Jefferies Financial Group Inc. Acquires Shares of 5,000 BioNTech SE (NASDAQ:BNTX)

Jefferies Financial Group Inc. purchased a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 5,000 shares of the company's stock, valued at approximately $570,000.

A number of other hedge funds also recently modified their holdings of the business. GF Fund Management CO. LTD. acquired a new position in shares of BioNTech during the fourth quarter worth $235,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of BioNTech by 19.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 221,080 shares of the company's stock worth $25,192,000 after purchasing an additional 36,746 shares during the period. USS Investment Management Ltd acquired a new position in shares of BioNTech during the fourth quarter worth $3,117,000. Tema Etfs LLC acquired a new position in shares of BioNTech during the fourth quarter worth $513,000. Finally, Stempoint Capital LP acquired a new position in shares of BioNTech during the fourth quarter worth $6,997,000. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Stock Up 2.2%

Shares of NASDAQ:BNTX traded up $2.54 during midday trading on Tuesday, hitting $115.64. 3,215,854 shares of the company's stock were exchanged, compared to its average volume of 937,107. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The stock has a 50 day moving average price of $98.19 and a 200-day moving average price of $108.26. The company has a market cap of $27.80 billion, a PE ratio of -55.07 and a beta of 1.35. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm's revenue for the quarter was down 19.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.90 earnings per share. On average, sell-side analysts anticipate that BioNTech SE will post -3.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BNTX has been the topic of a number of recent research reports. BMO Capital Markets lifted their price target on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. JPMorgan Chase & Co. dropped their target price on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Truist Financial restated a "buy" rating and issued a $155.00 target price (up previously from $151.00) on shares of BioNTech in a report on Tuesday. Morgan Stanley dropped their target price on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. Finally, Wall Street Zen lowered shares of BioNTech from a "hold" rating to a "sell" rating in a report on Friday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, BioNTech has an average rating of "Moderate Buy" and an average target price of $139.14.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.